Lipids, risk factors and ischaemic heart disease

Atherosclerosis

Volumn 124, Issue SUPPL., 1996, Pages

  Castelli, William P ^a  

^a Framingham Cardiovascular Institute   (United States)

Author keywords

Apolipoprotein E; Coronary heart disease; Framingham study; High density lipoprotein; Low density lipoprotein; Total cholesterol; Triglycerides

Indexed keywords

APOLIPOPROTEIN A4; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR;

ADULT; AGED; ATHEROGENESIS; CIGARETTE SMOKING; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0029756177     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05851-0     Document Type: Conference Paper

References (48)

1. Rigo P, Murray M, Strauss HW, et al. Left ventricular function in acute myocardial infarction evaluated by gated scintigraphy. Circulation 1974;50:678.
2. Reduto LA, Berger HJ, Cohen LS, et al. Sequential radionuclide assessment of left and right ventricular performance after acute transmural myocardial infarction. Ann Intern Med 1978;89:441.
3. Shah PK, Pichler M, Berman DS et al. Left ventricular ejection fraction determined by radionuclide ventriculography in early stages of first transmural myocardial infarction. Relation to short-term prognosis. Am J Cardiol 1980;45:542.
4. Dilsizian V, Bonow RO. Current diagnostic techniques of assessing myocardial viability in patients with hibernation and stunned myocardium. Circulation 1993;87:1.
5. Gotto AM Jr. Lipid lowering, regression, and coronary events. Circulation 1995;92:646.
6. Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: evidence for the 'hibernating myocardium'. J Am Coll Cardiol 1986;8:1467.
7. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657.
8. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801.
9. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915.
10. Mahley RW, Weisgraber KH, Innerarity TLK, Rall SC Jr. Genetic defects in lipoprotein metabolism: elevation of atherogenic lipoproteins caused by impaired catabolism. J Am Med Assoc 1991;265:78.
11. Wilson PF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia and coronary heart disease. The Framingham Offspring Study. J Am Med Assoc 1994;272:1666.
12. Kannel WB, Wolf PA, Garrison RJ. The Framingham Study. Section 34: Some risk factors related to the annual incidence of cardiovascular disease and death using pooled biennial measurements. Framingham Heart Study, 30 year follow-up. Bethesda, MD: National Heart, Lung and Blood Institute, 1987, NIH Publication 87-2703.
13. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol 1992;2:161.
14. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. Am J Med 1977;2:707.
15. Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation 1983;67:4.
16. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipo-proteins and the risk of myocardial infarction. N Engl J Med 1991;325:373.
17. Grover SA, Coupal L, Hu X-P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work. J Am Med Assoc 1995;274:801.
18. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease. Predicting risks by levels and ratios. Ann Intern Med 1994;121:641.
19. Wilson PWF, Kannel WB. Hypercholesterolemia and coronary risk in the elderly. The Framingham Study. Am J Geriatr Cardiol 1993;2:52.
20. Reis GJ, Kuntz RE, Silverman DI, Pasternak RC. Effects of serum lipid levels on restenosis after coronary angioplasty. Am J Cardiol 1991;68:1431.
21. Hokanson JE, Austin MA. Triglyceride is a risk factor of coronary disease in men and women. A meta-analysis of population based prospective studies. Circulation 1993;88:1.
22. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209.
23. Castelli WP. Epidemiology of triglycerides. A view from Framingham. Am J Cardiol 1992;70:3H.
24. Aberg H, Lithell H, Selinus I, Hedstrand H. Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris. Results from a 10-year follow-up of Uppsala primary prevention study. Atherosclerosis 1985;54:89.
25. Welin I, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G, Wilhelmsen R. Triglycerides a major coronary risk factor in elderly men. A study of men born in 1913. Eur Heart J 1991;12:700.
26. Steiner G. Hypertriglyceridemia and carbohydrate intolerance and therapeutic implications. Am J Cardiol 1986;57:27G.
27. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595.
28. Despres JP, Moorjani S, Tremblay A, et al. Relation of high plasma triglyceride levels associated with obesity and regional adipose tissure distribution to plasma lipoprotein-lipid composition in premenopausal women. Clin Invest Med 1989;12:374.
29. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - The Framingham Heart Study. Can J Cardiol 1988;4:5A.
30. Assmann G, Schulte H. Triglycerides and atherosclerosis: results from the Prospective Cardiovascular Munster Study. Atherosclerosis Rev 1991;22:51.
31. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85:37.
32. Schonfeld G. Changes in the composition of very-low-density lipoprotein during carbohydrate induction in man. J Lab Clin Med 1970;75:206.
33. Fry MM, Spector AA, Connor SL, et al. Intensification of hypertriglyceridemia by either alcohol or carbohydrate. Am J Clin Nutr 1973;26:798.
34. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196.
35. Witztum JL, Schonfeld G, Weidman SW. The effects of colestipol on the metabolism of very-low-density lipoproteins in man. J Lab Clin Med 1976;88:1008.
36. Poapst M, Steiner GL. Relative contribution of triglyceride-rich lipoprotein particle size and number to plasma triglyceride concentration. Artheriosclerosis 1985;5:381.
37. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495.
38. Campos H, Blijlevens E, McNamara JR, et al. LDL particle size distribution. Results from the Framingham Offspring Study. Arteriosclerosis Thromb 1992;12:1410.
39. Paramo JA, Colucci M, Collen D, Van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985;291:573.
40. Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992; 2:427.
41. Meade TW. Thrombosis and cardiovascular disease. Ann Epidemiol 1992;2:353.
42. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein (a) level and risk of coronary disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. J Am Med Assoc 1994;271:999.
43. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 1994;90:1688.
44. Bostom A, Cupples LA, Jenner J, et al. Elevated plasma lipoprotein (a) detected by electrophoresis predicts the development of premature coronary heart disease in men. In press.
45. Stamfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992;268:877.
46. Sellub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286.
47. Stamler J. Established major coronary risk factors. In: Marmot M and Elliot P. (eds). Coronary Heart Disease Epidemiology, from Etiology to Public Health. New York: Oxford University Press, 1992;55.
48. Castelli WP, Garrison RJ, Wilson PWF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. J Am Med Assoc 1986; 256:2835.